A six-month study of 539 people with type 2 diabetes at King Abdulaziz Hospital in Al-Ahsa, Saudi Arabia, found that patients taking two blood-sugar drugs together had a lower rate of heart failure than patients on one of the drugs alone. The same combination came with a catch. The two-drug group ended up with worse blood sugar control, not better.
The two drugs work in different ways. Dapagliflozin, sold by AstraZeneca as Farxiga, is an SGLT2 inhibitor that makes the kidneys dump excess sugar into the urine. Semaglutide ↗, the active ingredient in Novo Nordisk's Ozempic and Wegovy, is a GLP-1 receptor agonist that mimics a gut hormone called GLP-1, which curbs appetite and prompts the pancreas to release insulin after meals. Each drug has its own record of protecting the heart and kidneys in large trials. What doctors have less data on is whether stacking them adds up to more protection, or just more cost and more side effects.
The new cohort, published in the Journal of the ASEAN Federation of Endocrine Societies ↗, split its patients into those on dapagliflozin alone and those on dapagliflozin plus a once-weekly semaglutide injection, then followed their records for six months. On the heart side, the combination looked good. The relative risk of heart failure in the combination group was 0.43, meaning roughly 57 percent lower than the dapagliflozin-only group, and that gap was statistically significant (the study reported a p-value of 0.04, below the usual 0.05 cutoff for calling a result unlikely to be chance). The combination group also had higher HDL, the so-called good cholesterol, and better kidney filtration.
Two other heart numbers were softer. The combination group's risk of heart attack came in at 0.61, about 39 percent lower, but that did not clear the significance bar (p = 0.13), so it could be a real effect or it could be noise. Stroke showed no meaningful difference between the groups.
Then the finding that runs against expectations. Adding a GLP-1 drug usually pushes blood sugar down. Here, the dapagliflozin-only group had the greater drop in HbA1c, the three-month average blood sugar marker, and the combination group did worse on that measure. That is backwards from what the drugs' mechanisms predict, and it is the clearest sign that something other than the drugs is shaping the results.
The most likely something is who got which treatment. This was a retrospective study, meaning the researchers read back through records of care that had already happened rather than randomly assigning patients to a group. Doctors do not hand out a second injectable drug at random. They tend to add it for patients who are sicker, heavier, or harder to control, exactly the patients who would start with worse blood sugar and might carry more heart risk to begin with. The study adjusted for time and sex, but it could not adjust for the reasons a physician reached for the combination in the first place. The authors say as much, writing that causal relationships cannot be inferred and that residual confounding may exist.
That caveat is not boilerplate here. It is the whole story. A single-center, non-randomized, six-month look at 539 charts can show that the combination and lower heart failure rates traveled together. It cannot show that the combination caused the lower rate, and the reversed blood sugar result is a live reminder that the two groups were probably not the same kind of patient. The authors call for prospective trials, the kind that assign treatment up front and take the doctor's judgment out of the sorting, to test whether the pairing actually protects the heart.
For now the pairing of an SGLT2 drug and a GLP-1 drug is common in practice and biologically reasonable. This study adds a data point in its favor on heart failure and a caution flag on reading too much into any single real-world snapshot.